Renal effects of infusion of rilmenidine and guanabenz in conscious dogs

contribution of peripheral and central nervous system α2–adrenoceptors

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

We tested the renal effects of the α2‐adrenoceptor agonists, rilmenidine and guanabenz and the antagonists, 2‐methoxyidazoxan and idazoxan, in conscious dogs. Our aim was to test the hypothesis that putative imidazoline (I) receptors influence renal function. We reasoned that since rilmenidine and guanabenz are selective for I1‐ and I2‐binding sites respectively, an influence of one of these receptive sites on renal function would be reflected in qualitative differences between the effects of these agents. Moreover, effects mediated by putative I‐receptors should be relatively resistant to antagonism by the selective α2‐adrenoceptor antagonist, 2‐methoxyidazoxan. Since the effects of these drugs on renal function could be mediated in the central nervous system or periphery, the dogs were studied under both normal and ganglion‐blocked conditions. In dogs with intact autonomic reflexes, 2‐methoxyidazoxan (15 μg kg−1 plus 0.6 μg kg−1 min−1) produced effects consistent with a generalized increase in sympathetic drive, including increases in mean arterial pressure and plasma renin activity, and a reduction in sodium excretion. In ganglion‐blocked dogs, 2‐methoxyidazoxan reduced sodium excretion but had no discernible effect on systemic or renal haemodynamics. We conclude that an α2‐adrenoceptor‐mediated mechanism in the central nervous system tonically inhibits sympathetic drive in the conscious dog. In ganglion‐blocked dogs idazoxan (3‐300 μg kg−1) dose‐dependently increased arterial pressure. This was not abolished by concomitant administration of 2‐methoxyidazoxan (0.3‐30 μg kg−1). The pressor effect of idazoxan is therefore probably mediated by an agonist action at α‐adrenoceptors. The effects of infusions of rilmenidine (0.1‐1.0 mg kg−1) and guanabenz (10‐100 μg kg−1) were indistinguishable. They comprised dose‐dependent increases in mean arterial pressure, urine excretion, and glomerular filtration rate (the latter in ganglion blocked dogs only), and dose‐dependent reductions in heart rate, renal blood flow and sodium excretion (only in dogs with intact autonomic reflexes). All of these effects were antagonized by 2‐methoxyidazoxan. We conclude that the renal effects of rilmenidine and guanabenz infusions in conscious dogs are predominantly, if not completely, attributable to activation of α2‐adrenoceptors. Our results do not support the hypothesis that putative I‐receptors contribute towards the renal effects of these agents. 1995 British Pharmacological Society

Original languageEnglish
Pages (from-to)1557-1570
Number of pages14
JournalBritish Journal of Pharmacology
Volume116
Issue number1
DOIs
Publication statusPublished - 1995
Externally publishedYes

Keywords

  • central nervous system
  • conscious dog
  • imidazoline receptor
  • kidney
  • renal blood flow
  • sodium excretion
  • α ‐Adrenoceptors

Cite this

@article{8bb92e220da54e84b159bda95bb97194,
title = "Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system α2–adrenoceptors",
abstract = "We tested the renal effects of the α2‐adrenoceptor agonists, rilmenidine and guanabenz and the antagonists, 2‐methoxyidazoxan and idazoxan, in conscious dogs. Our aim was to test the hypothesis that putative imidazoline (I) receptors influence renal function. We reasoned that since rilmenidine and guanabenz are selective for I1‐ and I2‐binding sites respectively, an influence of one of these receptive sites on renal function would be reflected in qualitative differences between the effects of these agents. Moreover, effects mediated by putative I‐receptors should be relatively resistant to antagonism by the selective α2‐adrenoceptor antagonist, 2‐methoxyidazoxan. Since the effects of these drugs on renal function could be mediated in the central nervous system or periphery, the dogs were studied under both normal and ganglion‐blocked conditions. In dogs with intact autonomic reflexes, 2‐methoxyidazoxan (15 μg kg−1 plus 0.6 μg kg−1 min−1) produced effects consistent with a generalized increase in sympathetic drive, including increases in mean arterial pressure and plasma renin activity, and a reduction in sodium excretion. In ganglion‐blocked dogs, 2‐methoxyidazoxan reduced sodium excretion but had no discernible effect on systemic or renal haemodynamics. We conclude that an α2‐adrenoceptor‐mediated mechanism in the central nervous system tonically inhibits sympathetic drive in the conscious dog. In ganglion‐blocked dogs idazoxan (3‐300 μg kg−1) dose‐dependently increased arterial pressure. This was not abolished by concomitant administration of 2‐methoxyidazoxan (0.3‐30 μg kg−1). The pressor effect of idazoxan is therefore probably mediated by an agonist action at α‐adrenoceptors. The effects of infusions of rilmenidine (0.1‐1.0 mg kg−1) and guanabenz (10‐100 μg kg−1) were indistinguishable. They comprised dose‐dependent increases in mean arterial pressure, urine excretion, and glomerular filtration rate (the latter in ganglion blocked dogs only), and dose‐dependent reductions in heart rate, renal blood flow and sodium excretion (only in dogs with intact autonomic reflexes). All of these effects were antagonized by 2‐methoxyidazoxan. We conclude that the renal effects of rilmenidine and guanabenz infusions in conscious dogs are predominantly, if not completely, attributable to activation of α2‐adrenoceptors. Our results do not support the hypothesis that putative I‐receptors contribute towards the renal effects of these agents. 1995 British Pharmacological Society",
keywords = "central nervous system, conscious dog, imidazoline receptor, kidney, renal blood flow, sodium excretion, α ‐Adrenoceptors",
author = "Evans, {Roger G.} and Anderson, {Warwick P.}",
year = "1995",
doi = "10.1111/j.1476-5381.1995.tb16373.x",
language = "English",
volume = "116",
pages = "1557--1570",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Renal effects of infusion of rilmenidine and guanabenz in conscious dogs

T2 - contribution of peripheral and central nervous system α2–adrenoceptors

AU - Evans, Roger G.

AU - Anderson, Warwick P.

PY - 1995

Y1 - 1995

N2 - We tested the renal effects of the α2‐adrenoceptor agonists, rilmenidine and guanabenz and the antagonists, 2‐methoxyidazoxan and idazoxan, in conscious dogs. Our aim was to test the hypothesis that putative imidazoline (I) receptors influence renal function. We reasoned that since rilmenidine and guanabenz are selective for I1‐ and I2‐binding sites respectively, an influence of one of these receptive sites on renal function would be reflected in qualitative differences between the effects of these agents. Moreover, effects mediated by putative I‐receptors should be relatively resistant to antagonism by the selective α2‐adrenoceptor antagonist, 2‐methoxyidazoxan. Since the effects of these drugs on renal function could be mediated in the central nervous system or periphery, the dogs were studied under both normal and ganglion‐blocked conditions. In dogs with intact autonomic reflexes, 2‐methoxyidazoxan (15 μg kg−1 plus 0.6 μg kg−1 min−1) produced effects consistent with a generalized increase in sympathetic drive, including increases in mean arterial pressure and plasma renin activity, and a reduction in sodium excretion. In ganglion‐blocked dogs, 2‐methoxyidazoxan reduced sodium excretion but had no discernible effect on systemic or renal haemodynamics. We conclude that an α2‐adrenoceptor‐mediated mechanism in the central nervous system tonically inhibits sympathetic drive in the conscious dog. In ganglion‐blocked dogs idazoxan (3‐300 μg kg−1) dose‐dependently increased arterial pressure. This was not abolished by concomitant administration of 2‐methoxyidazoxan (0.3‐30 μg kg−1). The pressor effect of idazoxan is therefore probably mediated by an agonist action at α‐adrenoceptors. The effects of infusions of rilmenidine (0.1‐1.0 mg kg−1) and guanabenz (10‐100 μg kg−1) were indistinguishable. They comprised dose‐dependent increases in mean arterial pressure, urine excretion, and glomerular filtration rate (the latter in ganglion blocked dogs only), and dose‐dependent reductions in heart rate, renal blood flow and sodium excretion (only in dogs with intact autonomic reflexes). All of these effects were antagonized by 2‐methoxyidazoxan. We conclude that the renal effects of rilmenidine and guanabenz infusions in conscious dogs are predominantly, if not completely, attributable to activation of α2‐adrenoceptors. Our results do not support the hypothesis that putative I‐receptors contribute towards the renal effects of these agents. 1995 British Pharmacological Society

AB - We tested the renal effects of the α2‐adrenoceptor agonists, rilmenidine and guanabenz and the antagonists, 2‐methoxyidazoxan and idazoxan, in conscious dogs. Our aim was to test the hypothesis that putative imidazoline (I) receptors influence renal function. We reasoned that since rilmenidine and guanabenz are selective for I1‐ and I2‐binding sites respectively, an influence of one of these receptive sites on renal function would be reflected in qualitative differences between the effects of these agents. Moreover, effects mediated by putative I‐receptors should be relatively resistant to antagonism by the selective α2‐adrenoceptor antagonist, 2‐methoxyidazoxan. Since the effects of these drugs on renal function could be mediated in the central nervous system or periphery, the dogs were studied under both normal and ganglion‐blocked conditions. In dogs with intact autonomic reflexes, 2‐methoxyidazoxan (15 μg kg−1 plus 0.6 μg kg−1 min−1) produced effects consistent with a generalized increase in sympathetic drive, including increases in mean arterial pressure and plasma renin activity, and a reduction in sodium excretion. In ganglion‐blocked dogs, 2‐methoxyidazoxan reduced sodium excretion but had no discernible effect on systemic or renal haemodynamics. We conclude that an α2‐adrenoceptor‐mediated mechanism in the central nervous system tonically inhibits sympathetic drive in the conscious dog. In ganglion‐blocked dogs idazoxan (3‐300 μg kg−1) dose‐dependently increased arterial pressure. This was not abolished by concomitant administration of 2‐methoxyidazoxan (0.3‐30 μg kg−1). The pressor effect of idazoxan is therefore probably mediated by an agonist action at α‐adrenoceptors. The effects of infusions of rilmenidine (0.1‐1.0 mg kg−1) and guanabenz (10‐100 μg kg−1) were indistinguishable. They comprised dose‐dependent increases in mean arterial pressure, urine excretion, and glomerular filtration rate (the latter in ganglion blocked dogs only), and dose‐dependent reductions in heart rate, renal blood flow and sodium excretion (only in dogs with intact autonomic reflexes). All of these effects were antagonized by 2‐methoxyidazoxan. We conclude that the renal effects of rilmenidine and guanabenz infusions in conscious dogs are predominantly, if not completely, attributable to activation of α2‐adrenoceptors. Our results do not support the hypothesis that putative I‐receptors contribute towards the renal effects of these agents. 1995 British Pharmacological Society

KW - central nervous system

KW - conscious dog

KW - imidazoline receptor

KW - kidney

KW - renal blood flow

KW - sodium excretion

KW - α ‐Adrenoceptors

UR - http://www.scopus.com/inward/record.url?scp=0029083306&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.1995.tb16373.x

DO - 10.1111/j.1476-5381.1995.tb16373.x

M3 - Article

VL - 116

SP - 1557

EP - 1570

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 1

ER -